AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $285.00, with a market capitalization of 503.13B. The stock trades at a price-to-earnings (P/E) ratio of 81.73 and offers a dividend yield of 2.36%.
On 2026-10-21, AbbVie(ABBV) stock traded between a low of $282.16 and a high of $289.00. Shares are currently priced at $285.00, which is +1.0% above the low and -1.4% below the high.
AbbVie(ABBV) shares are trading with a volume of 4.39M, against a daily average of 5.63M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
ABBV News
AbbVie (ABBV Quick QuoteABBV - Free Report) closed at $284.80 in the latest trading session, marking a -1.48% move from the prior day. This move lagged th...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has stopped a Phase 1b study called “A Study to Assess the Adverse Events and...
AbbVie: Consistent Upward Revenue Trajectory AbbVie (ABBV +2.26%) primarily generates its revenue by developing advanced therapies across immunology, oncology,...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Investing Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead Social Security raises are locked to a government formula, but a growing numbe...
AbbVie (ABBV) is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance have successfully been completed for Elahere, and that a Le...
AbbVie (NYSE:ABBV) reported new clinical data for dual-targeting Crohn’s therapy ABBV-466, showing higher endoscopic remission rates than current monotherapies....
Kevin Warsh's Federal Open Market Committee (FOMC) has its next meeting on Oct. 28 to decide on a course of action for interest rates. It looks as if they aren'...
AbbVie (ABBV) and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 T...
AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopi...
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.